HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA)-Reference-Cited by-同舟云学术

HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA)

Published:2020-02-13 Issue:7 Volume:36 Page:588-593
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Cirillo Francesca¹,Catellani Cecilia¹,Lazzeroni Pietro¹,Sartori Chiara¹,Tridenti Gabriele¹,Vezzani Cristina¹,Fulghesu Anna Maria²,Madeddu Eleonora²,Amarri Sergio¹,Street Maria E.¹

Affiliation:

1. Department of Obstetrics Gynaecology and Paediatrics, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;

2. Department of Obstetrics and Gynaecology, University of Cagliari, Cagliari, Italy

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/09513590.2020.1725967

Reference64 articles.

1. Criteria, prevalence, and phenotypes of polycystic ovary syndrome

2. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline